Ferric citrate - PUMC Pharmaceutical

Drug Profile

Ferric citrate - PUMC Pharmaceutical

Alternative Names: FC 818

Latest Information Update: 06 Jan 2016

Price : $50

At a glance

  • Originator PUMC Pharmaceutical Company
  • Class Antianaemics; Ferric compounds; Hyperphosphataemia therapies; Small molecules; Tricarboxylic acids
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hyperphosphataemia

Most Recent Events

  • 06 Jan 2016 Phase-II clinical trials in Hyperphosphataemia in China (unspecified route) before January 2016
  • 06 Jan 2016 PUMC Pharmaceutical plans a phase III trial for Hyperphosphataemia in China (PUMC Pharmaceutical pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top